Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-09-25

Clinical Trial Update: Safety of KAE609 in Adults With Uncomplicated Plasmodium Falciparum Malaria. [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety of KAE609 in adults with uncomplicated Plasmodium falciparum malaria has completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • KAE609 (cipargamin)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Malaria | Phase 2 | Status: COMPLETED | Results posted: 2020-09-25